[
    "{\"step_by_step_thinking\": \"Enasidenib is specifically mentioned in multiple documents as a medication used to treat relapsed or refractory acute myeloid leukemia (AML) in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene. It has been approved by the U.S. Food and Drug Administration (FDA) for this indication. Therefore, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]